Background: There has been growing interest in the therapeutic potential of Cannabidiol (CBD) stemming from independent evidence that CBD has antipsychotic and anxiolytic properties in patients with mental health disorders. CBD has been found to be non-inferior to antipsychotic medication in a 4-week clinical trial in acute schizophrenia (Leweke et al 2012) and also has been found to reduce anxiety symptoms in social phobia and following public speaking. Human data also suggest that it attenuates the cognitive impairments associated with use of the main psychoactive ingredient in cannabis. However, whether CBD may be useful in relieving symptoms and distress in patients at clinical high-risk of psychosis (CHR) has never been tested. Furthermore, how the beneficial effect of CBD on psychotic and anxiety symptoms may be mediated in the brain remains unclear. The aim of the present study was to investigate whether short-term treatment with CBD was associated with preliminary evidence of therapeutic benefit and understand the neurocognitive mechanisms. Methods: We investigated the effects of short-term (21 days) treatment with CBD on psychotic and anxiety symptoms in 33 CHR patients, using a placebocontrolled, double-blind, parallel-arm design (CBD arm-16; placebo arm-17). In the subjects who received 21 days of treatment, we used fMRI in conjunction with a verbal memory task to assess the effect of CBD relative to placebo treatment on medial temporal and striatal function. Results: Of the 33 CHR patients recruited into the trial, 31 completed treatment for 21 days. Following 21-day treatment (intention-to-treat, last observation carried forward analysis), CBD-treated (n=16) CHR patients showed a significantly greater reduction in anxiety (p=0.02) and in distress associated with psychotic symptoms (p=0.03) and a trend (p=0.14) toward greater reduction in the severity of psychotic symptoms compared to those treated with placebo (n=17) CHR patients (Figure 4 ). In addition, CBD was tolerated as well as placebo. Consistent with our predictions, treatment with CBD (n=15) attenuated the engagement during verbal encoding of the parahippocampal cortex, but increased activation in the putamen in CHR patients. A similar pattern of activation was evident during verbal recall, with CBD treatment associated with increased engagement in the putamen. Discussion: Results from our proof-of-concept study suggest that 3-week treatment with CBD has beneficial effects on anxiety, attenuated psychotic symptoms and the distress associated with psychotic symptoms. They also suggest that short-term treatment with CBD modulates both medial temporal and striatal function in CHR patients, regions that are critically implicated in the CHR state. Coupled with the absence of significant adverse effects associated with CBD, a particularly important issue in relation to the treatment of CHR individuals, not all of whom develop a full-blown psychotic disorder, these data indicate that long-term treatment with CBD is likely to be efficacious in CHR patients.
POSSIBLE MECHANISMS INVOLVED IN THE ANTIPSYCHOTIC EFFECTS OF CANNABIDIOL (CBD)
Jose
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Background: Laboratory rodents and human studies have demonstrated that cannabidiol (CBD) presents antipsychotic effects. Several mechanisms of action have been associated to CBD effects. Most of the studies that have investigated these mechanisms have been performed in vitro and their relevance for the in vivo effects of this drug is still uncertain. Methods: In spite of its low affinity for CB1 receptor (CB1R), CBD is capable of antagonizing CB1R agonists at reasonable low concentrations. CBD can also inhibit anandamide uptake and metabolism, enhancing endocannabinoid tonus. It is also possible to attribute the antipsychotic action of CBD to an antagonism of CB1R. This suggestion was reinforced by the observation that patients in the initial prodromal states of psychosis and patients with schizophrenia had higher levels of anandamide in CSF than health controls. Moreover, there would be a decrease in glutamatergic inputs from this area to the prefrontal cortex, impairing locomotor activity and working memory and endocannabinoids could regulate this system. CBD could facilitate endocannabinoids "on demand" synthesis in post-synaptic neurons, acting pre-synaptic terminals and negatively regulating the release of neurotransmitters, particularly GABA and glutamate. Results: Also, an increase in anandamide levels induced by CBD could attenuate GABA release from ventral pallidum neurons, restoring the normal function of this system in psychotic patients. CBD can also increase adult neurogenesis in mice and that this effect has been shown to be dependent on the CB1 receptors. In addition to the mechanisms discussed above, CBD can produce several other effects that could also be involved to be responsible for its antipsychotic properties, including interaction with 5HT1A and TRPV1 receptors and anti-inflammatory/neuroprotective effects. CBD can act as a serotonin 1A receptor (5HT1A) agonist, although the role of 5-HT1A-mediated neurotransmission in schizophrenia is unclear, aripiprazole, an atypical antipsychotic, acts as a partial agonist at this receptor, an effect that could, together with its actions on D2 and 5-HT2A receptors, contribute to therapeutic effects of this drug. CBD can also activate Transient Receptor Vanilloid-1 (TRPV1) receptors that are expressed in several brain areas related to psychosis such as the prefrontal cortex, amygdala and hippocampus. Since CBD is also a potent anti-inflammatory, antioxidant and neuroprotective compound, it is possible that these effects are involved in its antipsychotic action. Discussion: Since CBD is also a potent anti-inflammatory, antioxidant and neuroprotective compound, it is possible that these effects are involved in its antipsychotic action.
TRACKING THE MECHANISMS UNDERLYING WORKING MEMORY DYSFUNCTION IN SCHIZOPHRENIA FROM CORTICAL MICROCIRCUITS TO THE SYSTEMS LEVEL Robert Bittner University Hospital Frankfurt, Goethe University
Overall Abstract: Converging behavioural and neuroimaging evidence indicates that an inability to regulate behaviour by working memory (WM) is a core feature of people with schizophrenia (PSZ) which significantly influences their level of recovery. WM dysfunction has also gained interest as a target of cognitive enhancement interventions and as an intermediate phenotype in the study of the genetic architecture of schizophrenia. These translational strategies critically depend upon a clear understanding of the underlying cognitive and neurophysiological disturbances. The aim of the symposium is to highlight current approaches to identify the pathophysiological mechanisms underlying WM deficits on both the microcircuit and the systems level. M. Ichinose will report cognitive modelling data showing that PSZ have elevated internal noise during perceptual processing, which was inversely correlated with WM precision. This indicates that 'noisy' perception contribute to impairments in WM and other cognitive domains. R. Bittner will present behavioural data from PSZ and imaging genetics fMRI data from a large cohort of healthy participants. The results of these studies indicate, that specific impairments in bottom-up attentional processes associated with genetic risk contribute to the dysfunction of working memory encoding in schizophrenia.
A. Anticevic will present computational microcircuit models, resting state fMRI data and fMRI data using ketamine which provide evidence for a disturbed excitation-inhibition (E-I) balance and resulting in large scale dysconnectivity in schizophrenia in the context of working memory and other cognitive processes. The research presented in this symposium integrates computational, neuroanatomical, electrophysiological, pharmacological, genetic, behavioural and neuroimaging methods to connect pathophysiological mechanisms at the microcircuit level such as increased neuronal noise and an abnormal E-I balance to disturbances in large scale brain networks at the systems level and to behavioral impairment. Such an integrative approach promises to yield new insights into the pathophysiology of cognitive dysfunction in schizophrenia.
MITOCHONDRIAL ALTERATIONS WITHIN THE PYRAMIDAL-PARVALBUMIN CELL MICROCIRCUIT IN THE PREFRONTAL CORTEX IN SCHIZOPHRENIA
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Background: Working memory, a core cognitive function impaired in schizophrenia, depends upon gamma oscillatory neuronal activity in the prefrontal cortex (PFC). Accordingly, individuals with schizophrenia show lower power of gamma oscillations in the PFC during tasks that involve working memory. Gamma oscillations emerge from the fast and coordinated activity of layer 3 excitatory pyramidal cells and inhibitory parvalbumin (PV) cells. As such, gamma oscillations have a particularly high energetic demand that is met by ATP production via oxidative phosphorylation (OXPHOS) within pyramidal and PV cell mitochondria. PFC layer 3 pyramidal cells have prominent reductions in OXPHOS-related gene pathways in schizophrenia. Importantly, OXPHOS can be regulated by two distinct processes: ATP demand to support neuronal firing, or upstream deficits in OXPHOS enzyme expression. Layer-and cell type-specific transcriptomic analyses of OXPHOS enzymes and ultrastructural analyses of mitochondrial morphology can help to distinguish between these two possibilities. Reduced ATP demand due to reduced neuronal firing is associated with 1) correlated expression levels of OXPHOS enzyme complexes, 2) lower expression of all subunits comprising Complex IV, the terminal and rate-limiting OXPHOS enzyme complex, and 3) normal mitochondrial morphology. Defective OXPHOS results in 1) elimination of correlated expression of OXPHOS enzyme complexes, 2) variable and inconsistent effects on Complex IV subunit expression, and 3) abnormal mitochondrial morphology. To determine which upstream factor is likely operative in the illness, we quantified OXPHOS enzyme complex transcripts in layer 3 pyramidal and PV cells, and performed ultrastructural analyses of mitochondrial morphology within pyramidal and PV axon boutons in layer 3 of the PFC in schizophrenia and unaffected comparison subjects. Methods: For mRNA analyses, frozen tissue sections of area 9 from 36 pairs of schizophrenia and comparison subjects were stained for Nissl substance to identify pyramidal cells, or labeled using immunoperoxidase for aggrecan to identify PV cells. Layer 3 pyramidal and PV somata were dissected using laser capture microdissection. Transcriptome profiling was performed by microarray using Affymetrix GeneChips. Analysis of Complexes I, IV, and V expression in each neuronal population was assessed at q<0.05 in covariate-and multiple comparisonscorrected analyses. Electron microscopic analyses were performed in area 46 of 2 matched pairs of schizophrenia and comparison subjects. Mitochondria in pyramidal and PV cell boutons were classified as normal or abnormal using established criteria. Chi-square analysis was used to examine whether the percentages of each type differed between groups. Results: The expression of subunits comprising Complexes I, IV, and V in layer 3 pyramidal and PV cells was significantly lower in subjects with schizophrenia relative to unaffected comparison subjects. In both cell populations, expression of Complexes I, IV, and V were correlated (r=0.8-0.9) in unaffected comparison and schizophrenia subjects. Complex IV subunits showed 11-26% reductions in pyramidal cells, and 7-31% reductions in PV cells in schizophrenia. In both unaffected comparison and schizophrenia subjects, ≥99% of mitochondria in pyramidal cell boutons and ≥97% of mitochondria in PV cell boutons exhibited normal morphology. Discussion: The current findings are most consistent with the interpretation that lower measures of OXPHOS in schizophrenia reflect lower demand for ATP production due to less neuronal firing. 
USING COMPUTATIONAL ESTIMATES
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Background: Heightened neural noise serves as a promising explanatory framework for schizophrenia (SZ) pathophysiology, yet its specific contribution to working memory (WM) deficits remains unclear. The perceptual template model (PTM), an established human-observer model of visual perception, asserts that a system's internal noise (IN) is due to both background, 'additive' noise and stimulus-driven 'unfiltered' noise. In this study, we assessed levels of PTM-derived additive and unfiltered IN in SZ during basic visual processing and tested their respective relations to patients' visuospatial WM imprecision. Methods: Individuals with SZ and demographically-matched healthy controls completed a perceptual discrimination task to estimate levels of IN and an analog visual WM task to examine the impact of internal noise on WM precision. The discrimination task involved distinguishing orientations of briefly presented gratings (1 cycle/°; tilted ±45° from vertical) embedded in varying levels of external noise (0-21%). Contrast thresholds were estimated, and additive and unfiltered IN levels were modeled from task performance with the PTM. The WM task required reproducing remembered orientations of high-contrast gratings (same size and spatial frequency as in the discrimination task) with a manual dial at a 1s delay. WM precision was computed as the concentration of the von Mises distribution, fit from subjects' orientation errors. Results: Additive and unfiltered IN during perceptual discrimination were both significantly increased in SZ compared to HC. WM precision was reduced in SZ compared to HC at every set size. Levels of unfiltered IN negatively correlated with WM precision in SZ, while both unfiltered and additive IN negatively correlated with WM precision in HC. For SZ, unfiltered IN was also negatively correlated with IQ, and WM precision was positively correlated with IQ in both groups. Discussion: We found evidence of elevated IN levels during visual perception in SZ, though only unfiltered IN was inversely related to patients' visual WM precision. Thus results indicate overall 'noisy' visual perception in SZ, but point to a more precise model of poorer signal filtering or noise suppression as contributing to WM deficits and potentially broader cognitive impairment. Future work must identify the neural drivers of IN levels, as they may shed light on differential implications of the excitation/inhibition imbalance in WM networks. Findings underscore the link between perception and WM encoding in SZ and offer a novel computational strategy for identifying common and unique pathophysiological mechanisms of SZ cognitive dysfunction.
